XOMA Royalty Corporation Common Stock (XOMA)

Price$42.09

Value ScoreD

Growth ScoreC

Momentum ScoreA

Favorite Metrics

Price vs S&P 500 (26W)23.07%

Price vs S&P 500 (4W)0.49%

VGM Score57.23

Market Capitalization$522.96M

P/E Ratio (Annual)16.49x

All Metrics

P/CF (Annual)182.15x

Book Value / Share (Quarterly)$9.48

P/TBV (Annual)5.56x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)105.26%

Cash Flow / Share (Quarterly)$0.57

Payout Ratio (TTM)16.35%

Price vs S&P 500 (YTD)50.13%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)69.63%

EPS (TTM)$2.00

10-Day Avg Trading Volume0.10M

EPS Excl Extra (TTM)$2.00

Revenue Growth (5Y)12.15%

EPS (Annual)$1.76

Dividend / Share (Annual)$0.46

ROI (Annual)14.89%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-217.61%

Cash / Share (Quarterly)$7.23

P/E Basic Excl Extra (TTM)15.47x

Revenue Growth QoQ (YoY)-22.59%

EPS Growth (5Y)8.80%

P/E Normalized (Annual)16.49x

ROA (Last FY)11.63%

Revenue Growth TTM (YoY)13.16%

EBITD / Share (TTM)$2.01

ROE (5Y Avg)-7.01%

Operating Margin (TTM)61.26%

Cash Flow / Share (Annual)$0.24

P/B Ratio4.63x

P/B Ratio (Quarterly)3.31x

Net Income / Employee (Annual)$2,265,100

EV / Revenue (TTM)11.13x

Net Interest Coverage (TTM)6.48x

ROA (TTM)13.12%

EPS Growth QoQ (YoY)182.04%

EV / EBITDA (TTM)16.34x

EPS Incl Extra (Annual)$1.76

Current Ratio (Annual)3.37x

Quick Ratio (Quarterly)3.58x

3-Month Avg Trading Volume0.21M

52-Week Price Return68.36%

EV / Free Cash Flow (Annual)188.16x

P/E Incl Extra (TTM)15.47x

Revenue / Employee (TTM)$3,468,200

Tangible BV / Share (Quarterly)$5.80

P/S Ratio (Annual)10.03x

Asset Turnover (Annual)0.19x

52-Week High$42.81

Operating Margin (5Y Avg)-226.62%

EPS Excl Extra (Annual)$1.76

Tangible BV CAGR (5Y)79.85%

26-Week Price Return31.00%

Quick Ratio (Annual)3.34x

13-Week Price Return59.98%

Total Debt / Equity (Annual)1.05x

Current Ratio (Quarterly)3.59x

Enterprise Value$540.20M

Revenue / Share Growth (5Y)2.56%

Asset Turnover (TTM)0.19x

Book Value / Share Growth (5Y)2.59%

Revenue / Employee (Annual)$3,724,900

Inventory Turnover (Annual)0.00x

Pretax Margin (Annual)61.01%

Cash / Share (Annual)$7.02

3-Month Return Std Dev36.86%

Gross Margin (5Y Avg)75.37%

Net Income / Employee (TTM)$2,415,000

EBITDA CAGR (5Y)23.38%

EBITDA Interim CAGR (5Y)-15.39%

ROE (Last FY)30.50%

Net Interest Coverage (Annual)3.92x

EPS Basic Excl Extra (Annual)$1.76

P/FCF (TTM)41.53x

Receivables Turnover (TTM)9.58x

EV / Free Cash Flow (TTM)79.51x

Total Debt / Equity (Quarterly)0.91x

EPS Incl Extra (TTM)$2.00

Receivables Turnover (Annual)15.49x

ROI (TTM)15.88%

P/S Ratio (TTM)10.77x

Pretax Margin (5Y Avg)-221.56%

Revenue / Share (Annual)$2.90

Tangible BV / Share (Annual)$4.99

Forward P/E90.29x

Free OCF CAGR (5Y)-22.21%

Price vs S&P 500 (52W)43.99%

P/E Ratio (TTM)15.47x

Year-to-Date Return58.29%

5-Day Price Return0.96%

EPS Normalized (Annual)$1.76

ROA (5Y Avg)-2.95%

Net Profit Margin (Annual)60.81%

Month-to-Date Return0.91%

Cash Flow / Share (TTM)$-2.74

EBITD / Share (Annual)$1.98

Operating Margin (Annual)62.53%

LT Debt / Equity (Annual)0.93x

P/CF (TTM)76.97x

ROI (5Y Avg)-2.77%

P/E Excl Extra (TTM)15.47x

LT Debt / Equity (Quarterly)0.79x

EPS Basic Excl Extra (TTM)$2.00

P/TBV (Quarterly)5.41x

Payout Ratio (Annual)17.26%

P/B Ratio (Annual)3.17x

Dividend / Share (TTM)$0.46

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)69.85%

Book Value / Share (Annual)$8.77

Price vs S&P 500 (13W)51.72%

Net Margin Growth (5Y)6.09%

Dividend Yield (TTM)1.06%

Beta0.86x

P/FCF (Annual)182.15x

Revenue / Share (TTM)$4.08

ROE (TTM)32.41%

52-Week Low$22.29

vGradeD

gGradeC

mGradeA

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.03est. 0.17

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.09

3.80

3.89

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
XOMAXOMA Royalty Corporation Common Stock	D	C	A	$42.09
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

XOMA Royalty Corp acquires future revenue rights from pre-commercial drug candidates licensed to pharmaceutical and biotechnology companies. This non-dilutive funding model enables biotech firms to advance their internal drug development without equity dilution. The company operates globally across the United States, Europe, Asia Pacific, and Switzerland.